2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive… Continue Reading

KEI comments in FDA-2017-N-3615

On November 17, 2017, KEI provided comments in KEI-FDA-2017-N-3615 These were the topics discussed: Transparency Clinical trial costs Data from the Orphan Drug program Costs of trials for government funded research Asset acquisition costs. Licensing Access to Knowhow, data and materials… Continue Reading


SCCR 35 Day 1 at WIPO Standing Committee on Copyright and Related Rights: will the “YouTube treaty” progress?

Day 1 at WIPO STANDING COMMITTEE ON COPYRIGHT AND RELATED RIGHTS Since 1998, the WIPO Standing Committee on Copyright and Related Rights (SCCR),has engaged in negotiations to create new norms for the protection of broadcasters, cablecasters and now –again– webcasters… Continue Reading